Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Cash (2020 - 2026)

Cytek Biosciences posted quarterly Change in Cash of -$25.2 million for Q1 2026, down 630.93% year-on-year from $4.7 million in Q1 2025, and down 937.82% on a QoQ basis from -$2.4 million in Q4 2025.

Cytek Biosciences (CTKB) has 7 years of Change in Cash data on file, last reported at -$25.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Cash fell 630.93% year-over-year to -$25.2 million; the trailing twelve-month figure through Mar 2026 stood at -$29.6 million (up 59.87% YoY), and the FY2025 full-year result was -$7.9 million, up 88.54% from the prior year.
  • Change in Cash for Q1 2026 stood at -$25.2 million, down from -$2.4 million in the prior quarter.
  • Across five years, Change in Cash topped out at $32.1 million in Q3 2023 and bottomed at -$167.1 million in Q1 2023.
  • The 5-year median for Change in Cash is -$3.4 million (2025), against an average of -$17.6 million.
  • The widest annual swing landed in 2023, when Change in Cash sank 7812.22%; it then surged 1132.59% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$42.0 million in 2022, then soared by 109.52% to $4.0 million in 2023, then tumbled by 1688.55% to -$63.6 million in 2024, then jumped by 96.18% to -$2.4 million in 2025, then slumped by 937.82% to -$25.2 million in 2026.
  • The last three Change in Cash figures came in at -$25.2 million (Q1 2026), -$2.4 million (Q4 2025), and $17.8 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -1.72 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -1.13 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -136.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -504.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -492.00 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 199.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.23 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 15.90 Mn
10 Cytek Biosciences - - 21.25 Mn -25.19 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -25.19 Mn
Dec 31, 2025 -2.43 Mn
Sep 30, 2025 17.81 Mn
Jun 30, 2025 -19.83 Mn
Mar 31, 2025 -3.45 Mn
Dec 31, 2024 -63.56 Mn
Sep 30, 2024 -15.62 Mn
Jun 30, 2024 8.78 Mn
Mar 31, 2024 1.51 Mn
Dec 31, 2023 4.00 Mn
Sep 30, 2023 32.09 Mn
Jun 30, 2023 -850,000.00
Mar 31, 2023 -167.11 Mn
Dec 31, 2022 -42.02 Mn
Sep 30, 2022 -8.37 Mn
Jun 30, 2022 -12.61 Mn
Mar 31, 2022 -2.11 Mn
Dec 31, 2021 409.15 Mn
Sep 30, 2021 -204.38 Mn
Jun 30, 2021 -8.74 Mn
Mar 31, 2021 2.47 Mn
Dec 31, 2020 130.59 Mn
Sep 30, 2020 206,000.00